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The limited packaging capacity of adeno-associated virus (AAV) precludes the design of vectors for the
treatment of diseases associated with larger genes. Autonomous parvoviruses, such as minute virus of mice and
B19, while identical in size (25 nm), are known to package larger genomes of 5.1 and 5.6 kb, respectively,
compared to AAV genomes of 4.7 kb. One primary difference is the fact that wild-type (wt) AAV utilizes three
capsid subunits instead of two to form the virion shell. In this study, we have characterized the packaging
capacity of AAV serotypes 1 through 5 with and without the Vp2 subunit. Using reporter transgene cassettes
that range in size from 4.4 to 6.0 kb, we determined that serotypes 1 through 5 with and without Vp2 could
successfully package, replicate in, and transduce cells. Dot blot analysis established that packaging efficiency
was similar for all vector cassettes and that the integrity of encapsidated genomes was intact regardless of size.
Although physical characterization determined that virion structures were indistinguishable from wt, trans-
duction experiments determined that all serotype vectors carrying larger genomes (5.3 kb and higher) trans-
duced cells less efficiently (within a log) than AAV encapsidating wt size genomes. This result was not unique
to reporter genes and was observed for CFTR vector cassettes ranging in size from 5.1 to 5.9 kb. No apparent
advantage in packaging efficiency was observed when Vp2 was present or absent from the virion. Further
analysis determined that a postentry step was responsible for the block in infection and specific treatment of
cells upon infection with proteasome inhibitors increased transduction of AAV encapsidating larger DNA
templates to wt levels, suggesting a preferential degradation of virions encapsidating larger-than-wt genomes.
This study illustrates that AAV is capable of packaging and protecting recombinant genomes as large as 6.0
kb but the larger genome-containing virions are preferentially degraded by the proteasome and that this block
can be overcome by the addition of proteasome inhibitors.
Adeno-associated virus (AAV) is a small, single-stranded
DNA dependovirus belonging to the parvovirus family. The 4.7
kb wild-type (wt) AAV genome is made up of two genes that
encode four replication proteins and three capsid proteins,
respectively, and is flanked on either side by 145-bp inverted
terminal repeats (ITRs) (28, 37). The virion is composed of
three capsid proteins, Vp1, Vp2, and Vp3, produced in a 1:1:10
ratio from the same open reading frame but from differential
splicing (Vp1) and alternative translational start sites (Vp2 and
Vp3, respectively) (30). Vp3 is the most abundant subunit in
the virion and participates in receptor recognition at the cell
surface defining the tropism of the virus. A phospholipase
domain, essential for viral infectivity, has been identified in the
unique N terminus of Vp1 (19, 53). The functional significance
of Vp2 remains to be resolved.
Similar to wt AAV, recombinant AAV (rAAV) utilizes the
cis-acting 145-bp ITRs to flank vector transgene cassettes, pro-
viding up to 4.5 kb for packaging of foreign DNA. Subsequent
to infection, rAAV can express the therapeutic gene and per-
sist without integration into the host genome by existing epi-
somally in circular head-to-tail concatemers (29). Although
there are numerous examples of rAAV success using this sys-
tem, in vitro and in vivo, limited packaging capacity has been
an impediment for AAV-mediated gene therapy of Duchenne
muscular dystrophy, hemophilia A, cystic fibrosis, and other
genetic diseases where the length of the coding sequence is
equal in size to the wt AAV genome. For most of the larger
genes mentioned above, this leaves little or no space for pro-
moter, polyadenylation, and enhancer sequences. Recently,
split vector systems, exploiting head-to-tail concatamerization
formation, have been developed to circumvent the small pack-
aging capacity of AAV genomes (13–16, 41, 52). The two
approaches, trans-splicing and homologous recombination
methods, depend upon recombination between two vector ge-
nomes (each genome encoding approximately half the trans-
gene) within the same cell to achieve gene expression. While
these approaches fundamentally solve current packaging limi-
tations of AAV, they create some disadvantages. Cells have to
be infected with numerous virus particles to increase the prob-
ability of transduction, and the system is reliant upon the
efficiency of homologous recombination.
With respect to wt AAV, two groups have characterized the
packaging capacity of AAV2. Hermonat et al. inserted incre-
ments of 100 bp into the wt AAV genome downstream of the
capsid gene (23). Viruses carrying larger genomes (up to 5.6
kb) were able to replicate and produce infectious virions, albeit
at reduced efficiency compared to wt. Dong et al. generated
packaging constructs, containing a completely recombinant ge-
nome encoding the chloramphenicol acetyltransferase (CAT)
gene, ranging in size from 1,918 to 6,019 bp (10). The latter
studies suggest that the optimum size of AAV2 vector genomes
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is between 4.1 and 4.9 kb. Based on these studies, the packag-
ing limits for AAV may differ depending on the presence of the
wt AAV sequence.
Other parvoviruses have been shown to package genomes as
large as 5.1 and 5.6 kb (minute virus of mice [MVM] and B19,
respectively). A striking structural difference is that MVM and
B19 are initially composed of two structural proteins (Vp1 and
Vp2), and the N termini of the minor capsid components (Vp1
and Vp2 for B19 and Vp2 for MVM) are exposed on the
surface of the virion subsequent to genome encapsidation. In
contrast, the N termini of Vp1 and Vp2 of AAV are located
within the virion (27, 46, 48). While Vp1 is required for infec-
tivity, Vp2 has been shown to be nonessential (44).
Based on this evidence, we wanted to explore the possibility
that producing a virion composed of only two capsid proteins
may enable AAV to package larger genomes more efficiently
than wt virions. We analyzed the packaging capacity of AAV
serotypes 1 through 5 with and without the minor capsid sub-
unit protein Vp2 using the previously characterized pAVCNst
packaging cassettes (10) (Fig. 1). The packaging efficiency of
each vector was quantitatively analyzed by dot blot hybridiza-
tion, the genome size by alkaline agarose gel analysis, and
transduction profile using CAT assays. In addition, similar
assays were simultaneously carried out on cystic fibrosis trans-
membrane conductance regulator (CFTR) cassettes of various
sizes. The additional transgene cassettes and the use of various
AAV serotypes were utilized to determine whether the DNA
sequence influenced the packaging efficiency and/or the pack-
aging capacity of related serotypes. This study suggests that all
AAV serotypes are capable of efficiently encapsidating ge-
nomes as large as 6 kb regardless of sequence, but the optimum
packaging capacity is 5.23 kb. Vectors carrying larger genomes
can be enhanced for more efficient transduction by the addi-
tion of proteasome inhibitors, suggesting a postentry block.
The data gathered from these studies provides important in-
formation regarding AAV vector design and suggests that
AAV packaging limits may not be restricted solely by the
physical size of the vector template.
METHODS AND MATERIALS
Cells and viruses. HeLa, 293, and COS-1 cells were maintained at 37°C in a
5% CO2 atmosphere in Dulbecco’s modified Eagle’s medium (Sigma, St. Louis,
Mo.) supplemented with 10% fetal bovine serum and penicillin-streptomycin.
Adenovirus dl309 has been described previously (24).
Plasmids. The AAV1 through 5 helper plasmids, pXR1 through pXR5 (32),
were used in these studies. These plasmids served as the starting reagents to
produce the Vp2 knockout mutant viruses ACA1 through ACA5 used in these
studies. The following oligonucleotides were designed and utilized in the
QuikChange multisite-directed mutagenesis kit (Stratagene) to mutate the Vp2
start codon ACG to ACA (shown in uppercase type): AAV1ACA, ttg agg aag gcg
cta agA CAg ctc ctg gaa aga aac g; AAV2ACA, ttg agg aac ctg tta agA CAg ctc
cgg gaa aaa aga gg; AAV3ACA, ttg agg aag cag cta aaA CAg ctc ctg gaa agaa agg;
AAV4ACA, ttg agc aag cgg gtg agA CAg ctc ctg gaa aga aga gac c; AAV5ACA, tga
aga ggg tgc taa gAC Agc ccc tac cgg aaa gc. Sequencing of miniprep DNA from
each of the mutagenized pXR1 to pXR5 plasmids was then done to verify the
start codon mutation. After verification, the resultant BsiWI/SwaI fragment
containing the mutation was then subcloned into the respective parent plasmid.
The CFTR, cytomegalovirus (CMV)-CFTR, and CMV(I)-CFTR cassettes were
produced from the pBQ4.7V CFTR plasmid generously provided to us by John
Olsen. This plasmid is the same as pBQ4.7 used by Drumm et al. (12), except a
450-bp piece at the end of the cDNA was replaced so there is a valine at
nucleotide 1475. Briefly, AgeI and NotI restriction sites were engineered 5 and
3 of the CFTR gene on the pBQ4.7V plasmid utilizing the Stratagene multisite-
directed PCR kit. TReGFP, with and without the simian virus 40 (SV40) intron,
and the pBQ4.7V plasmid were digested with AgeI and NotI enzymes. Each
digest was then PCR column purified (QIAGEN, Valencia, CA). The TReGFP
digest was then treated with calf intestinal phosphatase. The TReGFP backbone
and the CFTR fragment were gel extracted from the 0.7% agarose gel using the
gel extraction columns from QIAGEN. The TReGFP backbone and CFTR
fragment were then ligated overnight. The CFTR cassette lacking a promoter
was produced by digesting the CMV(I)-CFTR cassette with KpnI and AgeI to
remove the CMV and SV40 intron sequences. Klenow was then added to blunt
the ends followed by self-ligation overnight.
Production of recombinant AAV utilizing the CFTR and pAVCNst packaging
cassettes. To determine the effect of various genome sizes on the packaging
efficiency of AAV serotypes 1, 2, 3, 4, and 5 with and without capsid subunit Vp2,
we utilized the packaging plasmids pAVCNst acquired from Dong et al. (10).
pAVCNst plasmids D through L were used, ranging in size from 4,461 to 6,019
bp. Each construct contains the CMV immediate-early promoter with the chlor-
amphenicol acetyltransferase gene flanked by AAV2 ITRs. Recombinant AAV
was produced using a scaled-down version of the calcium phosphate triple plas-
mid transfection protocol (20). One 15-cm dish of 293 cells was transfected to
produce each of the viruses. Eighteen micrograms of XX6-80, 7.5 g of helper
plasmid (pXR1 to pXR5 series or the pXR1ACA to pXR5ACA series), 7.5 g
of the pAVCNst TR plasmid, 100 l of 2.5 M CaCl2, 870 l double-distilled
water, and 1 ml of 2 HeBS buffer (20) were mixed together and subsequently
added to each 15-cm dish after the calcium phosphate precipitate had formed.
The cells were then harvested at 48 h posttransfection by scraping the cells from
the plate. The cells were then pelleted at low-speed centrifugation (1,500 rpm),
the medium was then decanted, and the cell pellet was resuspended in 3 ml of 1
phosphate-buffered saline (PBS). Three cycles of freeze-thawing in dry ice-
methanol and a 37°C water bath were then performed. The cell homogenate
containing the rAAV was then divided into aliquots and stored at 80°C. rAAV
that was purified via CsCl gradients was produced by the calcium phosphate
triple transfection method using 5- by 15-cm plates of 293 cells. Cells were
scraped from each plate 48 h after transfection and pelleted by centrifugation for
5 min at 1,000 rpm in a Sorvall RT6000D centrifuge. All subsequent steps were
performed on ice unless otherwise noted. The cells were then resuspended in 10
ml of double-distilled water and sonicated 25 times using a Branson Sonifier set
to 50% duty and an output control of 5. One hundred microliters of DNase (10
mg/ml) was then added to the sonicated homogenate and incubated for 1 h in a
37°C water bath. CsCl (6.6 g) was then added to each sample and loaded into
Beckman Quick-Seal polyallomer centrifuge tubes. The samples were then cen-
trifuged at 65,000 rpm (402,000  g) for 5 h using the Beckman NVT65 rotor in
a Sorvall Ultra 80 centrifuge. Gradients were fractionated into 750-l fractions
FIG. 1. Vector sequence for the pAVCNst packaging cassettes
(10). Each cassette is composed of serotype 2 ITRs with a CMV
immediate-early (CMVie) promoter driving CAT gene expression. A
stuffer region was designated for cloning in DNA sequences to expand
the packagable genome. Letters on the left indicate different vectors.
The sizes of the stuffer DNA along with total vector genome size are
shown in the second and third columns, respectively.
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and stored at 20°C. AAV2 E, K, and L virus along with the CFTR vectors were
produced following the triple transfection method by transfecting 15- by 15-cm
plates of 293 cells, respectively. Cell homogenate was loaded onto iodixanol step
gradients as described previously (55), and rAAV was isolated from the 40 to
60% interface with a syringe. rAAV2 was then purified further by fast perfor-
mance liquid chromatography (FPLC) and heparin column chromatography.
Replication assays. Replication assays were carried out to determine whether
the proper size genomes were being replicated from the respective pAVCNst
packaging plasmids and packaged into all five AAV serotypes. 293 cells were
plated into 10-cm plates and transfected with 10 g XX680, 3.5 g pXR2 helper
plasmid, and 3.5 g pAVCNst packaging series D through L. Replication assays
were also conducted by infecting 293 cells, under conditions permissive for
replication, in 10-cm plates with 1  109 viral genomes. 293 cells were transfected
with 3.5 g of pXR2 and 10 g of XX680 6 h prior to infection. Cells were then
harvested 42 h postinfection, and low-molecular-weight DNA was isolated by
Hirt extraction. Samples were DpnI digested and fractionated on an agarose gel,
transferred to a HyBond N nylon membrane (Amersham Biosciences), and
probed overnight. This assay was used to assess the ability of rAAV to deliver its
genome to the nucleus and replicate.
Titer determination of rAAV. The presence and titer determination of DNA
containing viral particles was determined by DNA dot blot hybridization. Briefly,
10 l of each viral lysate sample was treated with 50 l of 0.1 g/l in 10 mM Tris
(pH 7.5)–10 mM MgCl2 for 1 h at 37°C. Fifty microliters of 100 mM EDTA was
then added to each sample, followed by incubation at 50°C with 50 l of pro-
teinase K–2.5% N-lauryl-sarcosyl solution for 45 min. Fifty microliters of 5 M
NaOH was then added to each sample and incubated for 20 min. The samples
were applied to a HyBond N membrane (Amersham Biosciences) through the
use of a dot blot manifold and probed overnight.
Electron microscopy. Peak fractions of rAAV2 E, K, and L were placed on a
400-mesh glow-discharged carbon grid by inversion on a 20-l drop of virus. The
grid was washed three times in 20 l of PBS for 1 min. The virus was then stained
for 1 min with 2% uranyl acetate. The virus was visualized by using a Zeiss EM
910 electron microscope.
Extraction of genomes from virions. DNA was extracted from each virus using
equal volumes of viral lysate in the study. The virus was incubated with 50 l of
0.1 g/l DNase I in 10 mM Tris (pH 7.5)–10 mM MgCl2 for at least 1 h at 37°C
to digest unpackaged genomes. Fifty microliters of 100 mM EDTA was then
added to each sample to deactivate DNase I, followed by incubation at 50°C with
50 l of proteinase K–2.5% N-lauryl-sarcosyl solution for 45 min to lyse the virus.
Viral DNA was extracted twice with phenol-chloroform and then precipitated
with 2 equivalent volumes of ethanol and 10% (vol/vol) 3 M sodium acetate.
Alkaline agarose gel electrophoresis was then carried out as described previously
(34a) to determine the size of the packaged genome. DNA size markers were
produced via single digests of the K pAVCNst plasmid with EcoRI and BamHI,
yielding the 4- and 5-kb-long DNAs, respectively.
CAT assays to analyze transduction efficiency. HeLa or COS-1 cells (6  105)
were plated in each 6-cm dish for AAV serotypes 1 to 3 and 4 and 5, respectively.
After the cells adhered to the dishes, they were infected with 500 genome-
containing virions per cell with an adenovirus (dl309) multiplicity of infection
(MOI) of 5. Cells were harvested 24 h after infection and lysed as described
previously (34a). CAT assays were then carried out on the protein homogenate
as described previously (34a) to assess the transduction profiles of rAAV sero-
types 1 through 5 with and without capsid subunit protein Vp2.
CFTR transduction assays. rAAV2 viruses were produced by utilizing the
following CFTR TR2 cassettes: (i) CFTR (5.1 kb), (ii) CMV-CFTR (5.7 kb), and
(iii) CMV(I)-CFTR (5.9 kb). HeLa cells (5  105) were plated in the wells of
six-well plates. HeLa cells were then infected with approximately 2,000 viral
genomes/cell of each AAV2-CFTR vector 8 hours after seeding the wells. At 48 h
postinfection, total RNA was isolated using the RNeasy column method (QIA-
GEN, Valencia, CA). Briefly, 350 l of RNeasy lysis buffer (RLT plus -mer-
captoethanol) was added to the pelleted HeLa cells for resuspension and lysis.
The lysate was then passed through a Qiashredder (QIAGEN). From this point,
the standard minicolumn protocol was followed and RNA was eluted in 30 l of
the supplied RNase-free water. poly(A) RNA was then isolated from 15 l of the
total RNA. The Oligotex mRNA mini kit (QIAGEN, Valencia, CA) was used to
isolate the mRNA from the total RNA according to protocol. mRNA was eluted
from the oligonucleotide T bead suspension using 60 l of supplied elution buffer
OEB (5 mM Tris, pH 7.5). Reverse transcription (RT)-PCR was then carried out
on the isolated mRNA utilizing the Superscript III first-strand system for RT-
PCR (Invitrogen). Briefly, 8 l of mRNA along with 1 l of 50 ng/l of random
hexamers and 10 mM deoxynucleoside triphosphates were incubated at 65°C for
5 min and cooled on ice for over 1 min. Ten microliters of cDNA synthesis mix
(2 l of 10 RT buffer, 4 l 25 mM MgCl2, 2 l 0.1 M dithiothreitol, 1 l
RNaseOUT, and 1 l SuperScript III RT) was added to the mRNA samples and
incubated at 25°C for 10 min followed by 50°C for 50 min. The reactions were
terminated by heating to 85°C for 5 min. One microliter of RNaseH was then
added to each tube and incubated at 37°C for 20 min. Three microliters of the
cDNA was then used in standard PCR using Taq polymerase to determine
whether CFTR transcripts were produced. To do this, primers specific for the
virally delivered CFTR transcript were utilized in the PCR to detect and amplify
the CFTR cDNA yielding a 450-bp fragment.
RESULTS
Packaging efficiency of AAV serotypes. In this study, we set
out to characterize the packaging capacity of AAV serotypes 1
through 5 with and without capsid subunit protein Vp2. Nine
CMV-driven chloramphenicol acetyltransferase pAVCNst
packaging cassettes ranging in size from 4,461 to 6,019 bp were
used (Fig. 1). An initial characterization of AAV serotypes
encapsidating the genomes of various sizes was carried out on
crude lysate virus as described in Materials and Methods to
more efficiently screen the 90 different viruses. Dot blot anal-
ysis was performed on the 90 different viruses after vector
production to determine whether the titer or packaging effi-
ciency was influenced by genome size. Table 1 summarizes the
range of vector titers acquired from three separate viral prep-
arations using the nine packaging cassettes (D through L).
Titers ranged from 106 to 108 viral genomes/l for a majority
of the viral preparations with little to no differences in titer
between AAV produced with the largest cassettes (3  106 to
9  107 viral genomes/l) compared to the wt size cassettes (6
 106 to 1  108 viral genomes/l). These data illustrate that
there is no apparent difference in packaging efficiency among
all five serotypes with and without Vp2.
Genome integrity of AAV serotypes. The dot blot method is
an effective method to quantitate viral titers, but it is incapable
of determining whether each AAV serotype has successfully
packaged the larger transgene cassettes in their entirety. Two
approaches were utilized to determine genome integrity after
encapsidation: direct lysis of the viral particles and isolation of
uncoated vector genomes from infected cells. In the first ap-
proach, viral DNA was isolated directly from each AAV sero-
type by treating the particles with DNase I to remove any
unpackaged DNA, followed by lysis using proteinase K and
detergent as described in Materials and Methods. The single-
stranded vector genomes were extracted and analyzed on al-
kaline agarose gels to determine size and integrity. A repre-
sentative Southern blot of an alkaline agarose gel of genomes
isolated from AAV1 is shown in Fig. 2. Half of the viral sam-
ples were subjected to DNase digestion prior to genome iso-
lation from the virions. This was done to determine whether
the larger genomes were packaged in their entirety and pro-
tected from DNase. Upon comparison of DNase-treated and
untreated samples of the same size, it is clear that the correct
size band is present with similar intensity. We have noted the
indication of DNA smearing in the DNase-treated and un-
treated samples in this Southern blot along with those from the
other serotypes, but the smearing is not extensive and is ho-
mogeneous throughout all of the samples tested (Fig. 2, lanes
7 and 22). Based on this assay, AAV serotypes 1 through 5 are
capable of packaging and protecting genomes as large as 6 kb.
Isolating DNA from AAV particles via direct lysis of the
virion with the method previously described (Fig. 2) does not
VOL. 79, 2005 PACKAGING LIMITATIONS OF AAV SEROTYPES 9935
discriminate between incompletely and completely assembled
virions that can effectively protect their genome from DNase I
digestion and carry out a successful infection. Intact AAV
particles that have assembled correctly comprise the essential
topology conformation necessary to successfully bind to its
cognate receptor and enter the cell, while the incompletely
assembled particles may lack this ability. This allowed us to
assess the genome content of infectious particles that entered
the cells and released their genomes within these cells. There-
fore, infection of 293 cells, made permissive for replication,
with AAV2 D through L vectors was carried out as described
in Materials and Methods. Approximately 40 to 42 h postin-
fection, the cells were harvested and low-molecular-weight
DNA was isolated by following the Hirt protocol. Figure 3
(top) illustrates that the AAV2 D through L viruses can infect
and deliver their respective genomes to the nuclei of 293 cells,
albeit at a decreased level for the K and L vectors with respect
to the others. Replicated monomer products can be detected
for all of the virally delivered packaging constructs, but the
replication dimer product for the L cassette is not detected at
these exposure times. DNA concentrations shown on the al-
kaline agarose gels and quantitated by dot blots are similar
between the AAV2 D through L viruses but do not correlate
with the infectivity of each virus. This suggests that the K and
L viral preparations may have an increased number of incom-
pletely assembled or defective particles, protecting the larger
genomes from DNase I digestion.
Based on this analysis, we carried out additional experiments
on the vector packaging cassettes that appeared compromised
in infectivity (i.e., cassettes E, K, and L). The next step was to
purify AAV encapsidating the E, K, and L genomes via CsCl
gradients and, in addition, AAV2 with iodixanol step gradients
followed by FPLC-heparin column purification. AAV vectors
purified under these conditions should decrease the population
of incompletely assembled or defective particles from the com-
pletely assembled virions in each vector preparation, especially
those encapsidating the K and L vector genomes based on
binding affinity to heparin columns, density in CsCl gradients,
and stability in salt. It is important to note that titers for the
purified serotypes encapsidating the E, K, and L genomes were
virtually equivalent (data not shown). As shown in Fig. 3 (bot-
tom), the Southern blot of Hirt DNA isolated from represen-
tative serotypes AAV1- and AAV3 (purified from CsCl)-in-
fected 293 cells suggests that all serotypes are capable of
packaging and infecting cells with genomes as large as 6 kb.
These results strongly support the viability of serotype vectors
carrying genomes larger than wt size after CsCl gradient puri-
fication. The blots also indicate that the dominant species
being delivered to the nucleus are full-length genomes. In
agreement with the infectivity data gathered from crude lysate
AAV2 infections in Fig. 3 (top), the infectivity of CsCl-purified
serotypes is reduced for virions encapsidating genomes of 5.3
kb (K) and 6 kb (L). Furthermore, transmission electron mi-
crographs of each viral preparation (Fig. 4) suggest that AAV
encapsidating larger genomes are similar in size and structure
to wt. Through use of this assay, it is apparent that higher
proportions of empty particles are present in the AAV2 K and
L viral preparations.
Analyzing CAT expression from infected cells. We next an-
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within the packaging constructs. Analyzing CAT expression
from infected HeLa cells enabled us to determine the trans-
duction profile of each serotype with and without Vp2. We
chose HeLa cells for this study because, in our hands, they are
transduced efficiently by AAV. HeLa cells were infected with
each AAV serotype at 500 viral genomes/cell and an adenovi-
rus MOI of 5 and harvested at 24 h postinfection. Figure 5 (top
panels) shows representative transduction profiles for AAV2
and AAV4 encapsidating the CAT packaging constructs. Four
to five time points were taken for each set of CAT assays, and
the reactions that were in the linear range were selected for
graphical representation. Variability in transfection efficiencies
can result in preparation-to-preparation variation in titer and
infectious-to-noninfectious particle ratios. To control for these
inconsistencies, transduction assays were carried out in dupli-
cate with separate viral preparations, and the transduction
profiles depicted in Fig. 5 (top and middle panels) were found
to hold true for each AAV serotype with and without Vp2.
Transduction profiles from CsCl-purified AAV1 and heparin
column-purified AAV2 E, K, and L are depicted in Fig. 5
(bottom panels). The heparin-purified AAV2 transduction ef-
ficiency is depicted as lower than the other profiles in Fig. 5
because this time point fell in the linear range in relation to the
kinetics of the CAT reaction. The transduction profiles dem-
onstrate that the difference in transduction efficiency between
AAV packaging the wt size and the K and L genomes consis-
tently ranged between three- to sevenfold. Based on the infec-
tivity data represented in Fig. 3, we expected the CAT trans-
duction profile to be lower for AAV encapsidating the K and
L genomes than for genomes of wt size. We found that AAV
lacking Vp2 displayed a transduction profile similar to that of
AAV with all three capsid proteins (Fig. 5, middle panels).
These data add more support to the previous claim that virions
lacking Vp2 do not encapsidate and transduce cells with the
larger genomes more efficiently. The functional relevance of
Vp2 in the life cycle of AAV remains to be resolved.
Effect of proteasome inhibitors on transduction. Protea-
some inhibitors have been described in numerous studies to
increase the transduction of rAAV postentry of the cell, sug-
gesting that proteasomes are a barrier for intracellular traf-
ficking (11, 51). To help understand and potentially eliminate
possibilities for why AAV encapsidating larger genomes (K
and L) are not as infectious as those with genomes near wt size,
we subjected each vector to various temperatures (37, 45, 56,
and 65°C) for 30 min and subjected HeLa cells to various
concentrations of the LLnL proteasome inhibitor prior to and
at the time of infection, respectively. The AAV serotypes in-
cluded in both studies were purified via CsCl gradients. The
AAV2 E and K vectors were resistant to the 37 and 45°C
temperatures based on transduction but were negatively af-
fected (twofold decrease) by the 56°C temperature. The L
vector was found to be more sensitive (twofold) to the 45 and
56°C temperatures than the E and K vectors, suggesting that
the stability of capsids are very similar. Little to no transduc-
tion was detected with any vector when exposed to 65°C (data
not shown). As shown in Fig. 6, the proteasome inhibitor
improved the transduction profiles of AAV encapsidating the
larger genomes to a greater extent than AAV encapsidating
the wt size genome in the presence of adenovirus. Transduc-
tion profiles of AAV encapsidating the E, K, and L genomes
were increased 1.1-, 2.2-, and 5.7-fold, respectively, in the pres-
ence of LLnL at a 40 M concentration. Upon comparison of
the K and L AAV1 transduction profile in the presence of the
proteasome inhibitor to that of the nontreated AAV1 E, it is
clear that transduction is restored to wt levels for the K vector
and to near wt levels for the L vector (less than twofold dif-
ference).
FIG. 2. Southern blot of vector DNA isolated directly from AAV virions and run on an alkaline agarose gel. The marker lanes contain DNA
fragments produced from pAVCNst K cassette that are 4 kb and 5 kb in size. The DNase control lane represents the pAVCNst K cassette digested
with DNase I to show that it was functional. Each set of bracketed lanes represents genomes isolated from AAV encapsidating each pAVCNst
vector. The numbers above each bracketed set signify the size of the vectors. The first two lanes in each bracketed set are wt capsid, and the second
set of two lanes is DNA isolated from the ACA (Vp2-less) mutants. DNase was added to the lysates of the second and fourth lanes in each
bracketed set (marked with asterisks). AAV DNA was labeled with a probe specific for the CAT gene. The single-stranded vector DNAs appear
as broad, blurry bands that are characteristic for AAV genomic DNA isolated from AAV capsids.
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Packaging full-length CFTR cassettes in AAV. To ensure the
above packaging data was not unique to the CAT transgene
cassettes, we tested a series of CFTR transgene cassettes for
vector infectivity as described above. Three CFTR cassettes
were constructed of various sizes, (i) CFTR with a TR-only
promoter as previously described (5.1 kb) (21), (ii) CMV-
CFTR (5.6 kb), and (iii) CMV(I)-CFTR (5.9 kb), and pack-
aged into AAV2. The CMV(I)-CFTR construct contains a
200-bp SV40 intron (I) between the CMV promoter and the
start of the CFTR gene, which has been shown to increase the
gene expression of other transgenes. Each virus was character-
ized for its ability to package its respective genome and infect
293 cells. Figure 7 (left) shows the Southern blot of Hirt DNA
isolated from infected 293 cells. It is clear that AAV is capable
of encapsidating each CFTR cassette in its entirety and infect-
ing target cells (Fig. 7, left lanes 3, 4, and 5).
Since we are not working with a reporter gene that can be
easily assessed by function, as is the case for CAT, we decided
to analyze each AAV2-CFTR virus’ ability to transduce cells by
the presence of CFTR mRNA. Briefly, HeLa cells were in-
fected with each CFTR vector at approximately 2,000 viral
genomes/cell in the presence and absence of LLnL (treatment
with LLnL not shown). The poly(A) RNA was then isolated
from the infected HeLa cells 48 h postinfection as described in
Materials and Methods. Reverse transcription-PCR was then
carried out on the isolated mRNA. Primers specific for the
virally delivered CFTR transcript were then used to detect and
amplify the CFTR cDNA transcripts in each sample. The
FIG. 3. (Top) Southern blot analysis of vector DNA isolated from infected 293 cells in the presence of transfected adenovirus helper (XX680)
and AAV2 helper (pXR2). AAV DNA was isolated from infected 293 cells by Hirt extraction and run on a 0.7% agarose gel. AAV DNA was
labeled with a probe specific for the CAT gene. The marker lanes contain DNA fragments produced from the pAVCNst K cassette that are 4 kb
and 5 kb in size. Replicated dimer genomes for the 5.3- and 6-kb genomes can be detected with extended exposure times. (Bottom) Southern blot
of vector DNA isolated from 293 cells infected with CsCl-purified AAV1 and 3 E, K, and L vectors in the presence of transfected adenovirus helper
(XX680) and AAV2 helper (pXR2). The sizes of the E (4,675 nucleotides [nts]), K (5,302 nts), and L (6,019 nts) vector genomes are depicted at
the top of the Southern blot. The correctly sized genomes and replication products are present within the cells. It is evident that the larger vectors
are not as efficient in delivery as the AAV encapsidating genomes of near wt size.
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450-bp PCR product was successfully amplified from each sam-
ple of infected cells, suggesting that AAV is capable of trans-
ducing cell lines with CFTR cassettes as large as 5.9 kb (Fig. 7,
right). A more sensitive assay, such as real-time PCR, would
have to be carried out to directly compare mRNA levels be-
tween cells infected in the presence or absence of LLnL. Fur-
ther studies regarding the CFTR vectors are currently ongoing
but are beyond the scope of this study.
DISCUSSION
The intricate biology of AAV as a nonpathogenic human
virus has led to its development into a promising viral vector
for gene therapy. However, its small size has been identified as
a major limitation for its use in therapies for diseases associ-
ated with larger genes, such as cystic fibrosis. Genome sizes
vary among the Parvovirus family but are independent of cap-
sid size. For example, the sizes of the B19, MVM, and AAV
genomes are 5.6, 5.1, and 4.7 kb, respectively, encapsidated in
a 25-nm capsid. What does differ structurally between these
viruses is that the B19 and MVM capsids are initially com-
posed of two capsid proteins, Vp1 and Vp2, and expose their
Vp2 N termini on the surface of the capsid for further pro-
cessing to Vp3 (MVM), while the Vp2 N termini of AAV are
located within the virion and are not processed. The unique N
terminus of Vp1 of B19 has also been described as being
surface exposed (26, 34). Based on this evidence, we wanted to
explore the possibility that producing a virion composed of
only two capsid proteins may enable AAV to package larger
genomes more efficiently than wt capsids. Our interests were
threefold: to determine the packaging capacity of AAV using
five different serotypes, to determine the repercussions the
encapsidated larger genomes had on infectivity, and to deter-
mine whether the Vp2-deficient AAV are capable of packaging
and infecting cells with larger genomes more efficiently than wt
capsids.
Virus particles display considerable diversity in size, compo-
sition, and structure, ranging from those containing a single
nucleic acid molecule and one structural protein to more com-
plex structures assembled from numerous different proteins
and other components. Some of these viruses have gained
attention as potential vectors for human therapies, leading to
numerous studies characterizing the packaging limitations of
viral vectors such as adenovirus (36-kb genome), SV40 (5-kb
genome), and Epstein-Barr virus (172-kb genome) (2, 3, 6).
The above studies have found that packaging capacity rarely
exceeds 105 to 110% of the size of the wt genome. In the case
of these viruses, fitness of the larger-genome-containing vi-
ruses was tested, resulting in the identification of deletions
over time. It is thought that a deletion process is being ampli-
fied by the packaging properties of each virus, leading to pre-
ferred/ideal size genomes and rescue of infectivity. In the case
of this study, fitness was not tested because it is not relevant
when producing vectors. The vector is only used for one round
of infection and not cycled, as described in the previous stud-
ies.
A study by Brandenburger et al. characterized the packaging
capacity of an autonomous parvovirus, MVM (4). The vectors
utilized in this study (ranging in size from 81 to 117% of wt
size) replaced part of the VP coding sequences with human
interleukin-2 cDNA, keeping the NS-1 and NS-2 genes intact.
Infectious particle production was best for vectors with ge-
nomes similar in size to that of wt MVM (5.1 kb). However,
genomes of identical size to wt but possessing sequence foreign
to wt showed dissimilar packaging efficiencies, alluding to the
importance of primary viral DNA sequence and possibly its
structure on packaging into the capsid. It is important to note
that ordered DNA structure has been identified in crystal
structures for canine parvovirus (CPV) and MVM, illustrating
that the genome is bound to the interior of the capsid by a
specific nucleotide-capsid interaction (1, 7, 47, 49). This con-
cept is further reinforced by CPV structural studies showing a
relationship between cis-acting, repeated DNA sequence mo-
tifs and specific amino acids on the capsid lumen (7). Varia-
tions of these sequence motifs were found throughout the CPV
genome. However, ordered DNA has yet to be discovered in
the crystal structures solved for AAV, suggesting that DNA-
FIG. 4. Transmission electron micrographs of AAV2 E, K, and L preparations. Peak fractions of the FPLC heparin column-purified AAV2
encapsidating the E, K, and L genomes were stained in 2% uranyl acetate and imaged by transmission electron microscopy. The small arrowhead
shows a genome containing rAAV2. The large arrowhead shows empty rAAV2 particles. The size and structure of each AAV vector is consistent.
However, more empty particles are evident in the K and L AAV2 vector preparations. nts, nucleotides.
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capsid interactions may be lacking or not as important for
AAV (42, 48). It has been shown that MVM and CPV virions
are dependent upon genome encapsidation for exposure of
their Vp2 N termini on the surface of the capsid for subsequent
proteolysis into Vp3 (1, 8, 45, 49). The nucleotide-capsid in-
teractions seem to lead to conformational changes necessary
for proper egress of the virus. AAV is not dependent on this
mechanism because its genome produces the Vp3 subunit from
an independent start codon. Based on our studies, it was dem-
onstrated that AAV is capable of packaging vector genomes as
large as 6 kb or approximately 130% the size of the wt genome
with similar efficiency. In support of our study, a recent in vivo
study by Sarkar et al. utilized AAV8 to package a 5.6-kb canine
FVIII cDNA construct that was later found to give 100%
correction of plasma FVIII activity in a hemophilia A mouse
model (35). Although this study determined that the larger
genome affected infectivity, enough vector gene product was
generated to alter the diseased phenotype. With this evidence
FIG. 5. Functional assay for the CAT transgene. HeLa cells (6  105) were infected with 500 viral genomes/cell with an adenovirus MOI of
5. Cell homogenate was collected from the HeLa cells at 24 h postinfection. CAT assays were carried out on 30 l of protein homogenate from
the infected HeLa cells. Transduction was normalized to the protein concentration for each sample. CAT activity is represented on the vertical
axes in counts per minute (cpm) of radioactivity, and the horizontal axes indicate the sizes of the AAV vectors. (Top panels) Graphical
representation of CAT transduction with wt capsid AAV2 and AAV4. (Middle panels) Graphical representation of CAT transduction for the
Vp2-less (ACA) AAV2 and AAV4. (Bottom panels) CAT transduction profiles of CsCl-purified AAV1 E (4,675 nucleotides), K (5,302 nucleo-
tides), and L (6,019 nucleotides) and heparin column-purified AAV2 E, K, and L. CAT activity was measured to be three- to sevenfold lower for
the K and L vectors than for the E and F vectors for serotypes 1 through 5.
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in hand, it is possible to hypothesize that AAV has a higher
tolerance for foreign DNA because it may not be dependent on
specific nucleotide-capsid interactions within the virion and in
turn is capable of packaging larger genomes. However, there
may be a preferred sequence context (e.g., the AAV2 genome
is made up of 54% GC content), and this bias may explain
previous observations of certain vector transgenes yielding
higher titers than others of identical size (unpublished data).
Infectivity of AAV encapsidating larger genomes. Figure 8
shows the predicted infectious pathway of AAV2. The early
steps of AAV infection involve attachment to a variety of cell
surface receptors such as HSPG, FGFR, v5 integrin, and
hepatocyte growth factor receptor (c-Met) (Fig. 8I) (9, 25, 31,
39, 40), followed by clathrin-dependent endocytosis (Fig.8II).
Studies have been carried out by a number of groups (11, 22,
50, 51) illustrating that drugs/chemicals such as bafilomycin A,
brefeldin A, and MG-132 augment rAAV transduction by act-
ing on the level of endosome acidification, early-to-late endo-
some transition, and proteasome activity, respectively. Based
on these studies, it has been proposed that AAV requires
endosomal acidification to escape from the late endosome and
traffic to the nucleus (Fig. 8III and IV). Use of proteasome
inhibitors such as MG-132 and LLnL have been shown to
increase transduction, providing evidence that after endosome
escape, AAV must elude proteasomes in the cytoplasm while
traversing to the nucleus (Fig. 8IV and V) (11, 51). It was
recently determined that AAV capsids are ubiquitinated,
marking them for degradation by the proteasome (Fig.8IV)
(50), adding more support to the notion that proteasomes in
the cytoplasm act as barriers to AAV infection. This study
suggests that AAV is capable of encapsidating genomes as
large as 6 kb with similar efficiencies as genomes of wt size
(Table 1 and Fig. 2). However, these larger-genome-containing
virions were found to be less infectious (within a log) than
those containing genomes of wt size (Fig. 3). The inability of
these viruses to infect cells efficiently was not due to their
inability to bind and internalize into cells or package incom-
plete genomes (Fig. 3). Hirt analysis and proteasome inhibitor
studies determined that the block in the infectious pathway was
postentry. As depicted in Fig. 8, AAV is shown to have three
potential endpoints postentry based on what is known of
AAV2 intracellular trafficking. The first occurs when AAV is
FIG. 6. CAT transduction profile of proteasome inhibitor (LLnL)-
treated HeLa cells. HeLa cells (6  105) were infected with 500 viral
genomes/cell of AAV1 E, K, and L vectors with an adenovirus MOI of
5 and 40 M LLnL. Cell homogenate was collected from the HeLa
cells at 24 h postinfection. CAT assays were carried out on 30 l of
protein homogenate from the infected HeLa cells. Transduction was
normalized to the protein concentration for each sample. The gray
bars represent the untreated HeLa cells, and the black bars represent
HeLa cells treated with 40 M LLnL. LLnL is shown to increase CAT
activity preferentially for the K and L vectors compared to the E
vector.
FIG. 7. (Left) Southern blot analysis of CFTR vector DNA isolated from infected 293 cells with CsCl-purified AAV2-CFTR (5.1 kb),
AAV2-CMV-CFTR (5.6 kb), and AAV2-CMV(I)-CFTR (5.9 kb) virus in the presence of transfected adenovirus helper (XX680) and AAV2
helper (pXR2). CFTR vector DNA was isolated from infected 293 cells by Hirt extraction and run on a 0.7% agarose gel. CFTR vector DNA was
labeled with a probe specific for the CFTR gene. Replicated monomer and dimer products can be seen for each vector at the correct size based
on the 4.7- and 5.7-kb markers. The arrows present in the AAV2-CMV-CFTR and AAV2-CMV(I)-CFTR lanes represent the locations of the
replicated dimer products that are present on longer exposures. (Right) Reverse transcription-PCR of poly(A) RNA isolated from AAV2-CFTR-,
AAV2-CMV-CFTR-, and AAV2-CMV(I)-CFTR-infected HeLa cells. HeLa cells (5  105) were infected with each virus at approximately 2,000
viral genomes/cell. The poly(A) RNA was then isolated from the infected HeLa cells at 48 h postinfection as described in Materials and Methods.
Primers specific for the virally delivered CFTR gene were used to detect and amplify 450 bp of the CFTR transcripts. Each CFTR vector is capable
of transducing the cell line of interest.
VOL. 79, 2005 PACKAGING LIMITATIONS OF AAV SEROTYPES 9941
unable to escape the late endosome and is routed to the lyso-
some for degradation (Fig. 8IV). The second and third occur
after AAV has escaped from the endosome and is trafficking
toward the nucleus. Data based on autonomous parvoviruses
suggest that, prior to escaping the endosome, the virion is
thought to undergo conformational changes, leading to the expo-
sure of the unique N terminus of Vp1, necessary for escape (Fig.
8III) (5, 33). However, exposure of Vp1 may not be the only
factor involved in escape from the endosome, as was indicated in
a recent study with CPV (38). Once AAV is in the cytoplasm en
route to the nucleus, the virion is thought to be ubiquitinated (Fig.
8IV), thereby being targeted for degradation by the proteasome.
Those that escape degradation by the proteasome reach the nu-
cleus and deliver their genome. Our studies using the proteasome
inhibitor LLnL suggest that AAV encapsidating larger genomes
are degraded at a higher frequency than those with genomes of wt
size. Infectivity/transduction were restored to wt or near wt levels
for AAV encapsidating the 5.3- and 6-kb genomes, respectively,
shifting the balance from proteasome degradation to nuclear ac-
cumulation, resulting in increased transduction (Fig. 6). These
data support the model illustrated in Fig. 8 and identify an area of
AAV trafficking that will require more rigorous studies in the
future.
Impact on packaging large genes. Numerous studies have
addressed the issue of efficiently packaging the CFTR gene
with a small promoter into AAV capsids (17, 18, 36, 43, 54).
These studies identified truncated forms of CFTR that are
functional when tested for activity using the patch-clamp
method. Utilizing these truncated forms of CFTR in AAV
vector cassettes created additional space to incorporate short
promoter elements such as chicken -acting, Rous sarcoma
virus long terminal repeat, and the AAV p5 promoter while
remaining close to 5 kb in size. These AAV-CFTR vectors
were shown to efficiently package and deliver the CFTR trans-
gene to the target cells displaying CFTR mRNA production
and chloride channel activity. Normal levels of CFTR in airway
epithelia suggest highly regulated gene expression is at play.
Our studies support the possibility of constructing transgene
cassettes for larger genes with a promoter of interest, such as
a regulatable promoter (Fig. 7). However, a significant propor-
tion of AAV encapsidating genomes larger than 5.2 kb appear
to be targeted favorably for proteasome degradation. A com-
bined approach utilizing proteasome inhibitors appears to be
capable of reestablishing transgene expression levels for vec-
tors greater than 5.2 kb in size to levels comparable to those
encapsidating vectors of wt size. In regard to the previous
studies utilizing truncated forms of CFTR, this study suggests
that an additional 200 bp of DNA sequence can be incorpo-
rated into these vectors, generating AAV that will efficiently
transduce cells without the aid of proteasome inhibitors.
FIG. 8. Predicted model based on AAV2 trafficking. (I) The first step in AAV2 infection is binding to its primary receptor heparan sulfate
proteoglycan and to a secondary receptor. (II) AAV becomes endocytosed via clathrin-coated pits and is brought into the cell in an early endosome.
(III) The early endosome then matures into a late endosome as the pH begins to drop to around 5. A pH-dependent conformational change occurs
that is thought to expose the N terminus of Vp1, providing the phospholipase activity aiding in endosome escape. (IV) At this point in the pathway,
AAV either fails to escape the late endosome, where it later becomes degraded by the lysosome, or escapes into the cytoplasm perinuclearly, where
it becomes ubiquitinated. (V) The ubiquitinated virions are then recognized by cytoplasmic proteasomes on their way to the nucleus where they
are degraded, but those that avoid interaction with the proteasomes reach the nucleus for genome delivery.
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This study suggests that AAV encapsidating genomes larger
than 5.2 kb are not influenced by the presence or absence of
Vp2, distinguishing autonomous parvoviruses from AAV. The
addition of proteasome inhibitor at the time of infection was
shown to augment transduction of the larger vectors to levels
similar to AAV encapsidating vector cassettes of wt size, sug-
gesting that the larger vectors are capable of carrying out a
successful infection. These modifications can easily be adapted
to current AAV vector studies and suggest that a better un-
derstanding of virus infection may lead to genetic approaches
that will facilitate efficient packaging and transduction of vec-
tor transgene cassettes larger than wt size.
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